Gene info: ID 54764

Gene: ZRANB1

GENE ID: 54764

Synonyms: TRABID

Description: zinc finger RANBP2-type containing 1

Gene type: protein-coding

Location: 10q26.13

dbXrefs: Ensembl:ENSG00000019995 MIM:611749 Vega:OTTHUMG00000019223 UniprotKB:Q9UGI0

RefSeq: NC_000010.11

Retrived from: SNP Mapped

SNPs: 1 ANCO-SNPs

Phenotype: AD

# Publications: 0

Sherlock p-value : NA (AD) NA (ND) (Frontal_Cortex)

Pascal p-value : 9.127e-1 (AD) 1.451e-1 (ND)

ANCO-SNPs

SNP ID	Position	Alleles	Trait	Variation Type
rs11596226	chr10:124986796 (GRCh38.p7)	T>G	alcohol dependence	SNV(Single Nucleotide Variation)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
SENP2	0.954
API5	0.941
BAG5	0.939
RPRD1A	0.938
MKRN1	0.937
SLU7	0.937
MATR3	0.937
PAFAH1B2	0.937
USP7	0.936
MPHOSPH8	0.935

Top 10 negatively co-expressed genes

Gene Symbol	Pearson Correlation Coefficient
OR4F5	-0.704
OR4F29	-0.698
KLRB1	-0.31
MTRNR2L10	-0.302
TFPI2	-0.291
MTRNR2L6	-0.28
CSAG1	-0.279
MTRNR2L9	-0.276
TIGIT	-0.276
MTRNR2L3	-0.276

There is no DrugBank record for this gene !

ID	Drug Name	Action	PubMed
C051246	1-methylanthracene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZRANB1 mRNA	28329830
D016604	Aflatoxin B1	Aflatoxin B1 results in increased expression of ZRANB1 mRNA	19770486
D018501	Antirheumatic Agents	Antirheumatic Agents results in increased expression of ZRANB1 mRNA	24449571
C006632	arsenic trioxide	arsenic trioxide results in increased expression of ZRANB1 mRNA	20458559
C547126	AZM551248	AZM551248 results in decreased expression of ZRANB1 mRNA	22323515
C006780	bisphenol A	bisphenol A results in decreased methylation of ZRANB1 promoter	27312807
C018475	butyraldehyde	butyraldehyde results in decreased expression of ZRANB1 mRNA	26079696
D019256	Cadmium Chloride	Cadmium Chloride results in increased expression of ZRANB1 mRNA	21457566
D019327	Copper Sulfate	Copper Sulfate results in increased expression of ZRANB1 mRNA	19549813
D016572	Cyclosporine	Cyclosporine results in decreased expression of ZRANB1 mRNA	19770486
C007738	fluoranthene	[1-methylanthracene co-treated with fluoranthene] results in increased expression of ZRANB1 mRNA	28329830
D005557	Formaldehyde	Formaldehyde results in decreased expression of ZRANB1 mRNA	20655997
D005947	Glucose	[INS protein co-treated with Glucose] results in decreased expression of ZRANB1 mRNA	22634610
C410337	K 7174	K 7174 results in increased expression of ZRANB1 mRNA	24086573
D058185	Magnetite Nanoparticles	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of ZRANB1 mRNA	21641980
D058185	Magnetite Nanoparticles	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of ZRANB1 mRNA	26378955
C004925	methylmercuric chloride	methylmercuric chloride results in decreased expression of ZRANB1 mRNA	28001369
D037742	Nanotubes, Carbon	"Nanotubes, Carbon analog results in decreased expression of ZRANB1 mRNA"	25554681
D037742	Nanotubes, Carbon	"Nanotubes, Carbon results in decreased expression of ZRANB1 mRNA"	25554681
C046012	pentanal	pentanal results in decreased expression of ZRANB1 mRNA	26079696
D010634	Phenobarbital	Phenobarbital affects the expression of ZRANB1 mRNA	19159669
C006253	pirinixic acid	pirinixic acid results in increased expression of ZRANB1 mRNA	17426115
D011374	Progesterone	Progesterone results in increased expression of ZRANB1 mRNA	23012394
C009277	sodium arsenate	sodium arsenate results in increased expression of ZRANB1 mRNA	21795629
D004113	Succimer	[Succimer binds to Magnetite Nanoparticles] which results in decreased expression of ZRANB1 mRNA	21641980
D004113	Succimer	[Succimer co-treated with Magnetite Nanoparticles] results in decreased expression of ZRANB1 mRNA	26378955
D013749	Tetrachlorodibenzodioxin	Tetrachlorodibenzodioxin affects the expression of ZRANB1 mRNA	21570461\|2468072
C009495	titanium dioxide	titanium dioxide results in increased expression of ZRANB1 mRNA	23409001
D014212	Tretinoin	Tretinoin results in increased expression of ZRANB1 mRNA	23724009
C057693	troglitazone	troglitazone results in decreased expression of ZRANB1 mRNA	28973697
D014520	Urethane	Urethane results in increased expression of ZRANB1 mRNA	28818685
D014635	Valproic Acid	Valproic Acid affects the expression of ZRANB1 mRNA	25979313
D014635	Valproic Acid	Valproic Acid results in decreased expression of ZRANB1 mRNA	23179753\|2800136
D014635	Valproic Acid	Valproic Acid results in increased expression of ZRANB1 mRNA	29154799
D001335	Vehicle Emissions	Vehicle Emissions results in increased methylation of ZRANB1 gene	25560391

GO/Pathway

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0004843	thiol-dependent ubiquitin-specific protease activity	-	IBA	21873635
GO:0004843	thiol-dependent ubiquitin-specific protease activity	-	IDA	18281465 23827681
GO:0005515	protein binding	-	IPI	11463333 18281465 19373254
GO:0036459	thiol-dependent ubiquitinyl hydrolase activity	-	IMP	18281465
GO:0046872	metal ion binding	-	IEA	-
GO:0070530	K63-linked polyubiquitin modification-dependent protein binding	-	IBA	21873635
GO:0070530	K63-linked polyubiquitin modification-dependent protein binding	-	IDA	18281465

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0007010	cytoskeleton organization	-	IBA	21873635
GO:0007010	cytoskeleton organization	-	IMP	21834987
GO:0016055	Wnt signaling pathway	-	IEA	-
GO:0016477	cell migration	-	IBA	21873635
GO:0016477	cell migration	-	IMP	21834987
GO:0016579	protein deubiquitination	-	TAS	-
GO:0022604	regulation of cell morphogenesis	-	IMP	21834987
GO:0030177	positive regulation of Wnt signaling pathway	-	IBA	21873635
GO:0030177	positive regulation of Wnt signaling pathway	-	IMP	18281465
GO:0035523	protein K29-linked deubiquitination	-	IBA	21873635
GO:0035523	protein K29-linked deubiquitination	-	IDA	23827681
GO:0070536	protein K63-linked deubiquitination	-	IDA	23827681
GO:0070536	protein K63-linked deubiquitination	-	IMP	18281465
GO:0071947	protein deubiquitination involved in ubiquitin-dependent protein catabolic process	-	IBA	21873635
GO:0071947	protein deubiquitination involved in ubiquitin-dependent protein catabolic process	-	IMP	18281465
GO:1990168	protein K33-linked deubiquitination	-	IBA	21873635
GO:1990168	protein K33-linked deubiquitination	-	IDA	23827681 24768539

GO ID	GO Term	Qualifier	Evidence	PubMed
GO:0005634	nucleus	-	IBA	21873635
GO:0005634	nucleus	-	IDA	11463333
GO:0005654	nucleoplasm	-	IDA	-
GO:0005737	cytoplasm	-	IBA	21873635
GO:0005737	cytoplasm	-	IDA	11463333 21834987
GO:0005829	cytosol	-	IDA	-
GO:0005829	cytosol	-	TAS	-
GO:0043231	intracellular membrane-bounded organelle	-	IDA	-

KEGG ID	KEGG Term

Reactome ID	Reactome Term	Evidence
R-HSA-392499	Metabolism of proteins	TAS
R-HSA-5688426	Deubiquitination	TAS
R-HSA-5689896	Ovarian tumor domain proteases	TAS
R-HSA-597592	Post-translational protein modification	TAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID	Title (Year)	Author	Journal